

Product datasheet for **TL314768V**

Annexin VI (ANXA6) Human shRNA Lentiviral Particle (Locus ID 309)

Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	Annexin VI (ANXA6) Human shRNA Lentiviral Particle (Locus ID 309)
Locus ID:	309
Synonyms:	ANX6; CBP68; CPB-II; p68; p70
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	ANXA6 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 ⁷ TU/ml.
RefSeq:	<u>NM_001155</u> , <u>NM_001193544</u> , <u>NM_004033</u> , <u>NM_001155.1</u> , <u>NM_001155.2</u> , <u>NM_001155.3</u> , <u>NM_001155.4</u> , <u>NM_004033.1</u> , <u>NM_004033.2</u> , <u>NM_001193544.1</u> , <u>BC017046</u> , <u>BC017046.1</u> , <u>BM904172</u> , <u>NM_001363114</u> , <u>NM_001155.5</u>
UniProt ID:	<u>P08133</u>
Summary:	Annexin VI belongs to a family of calcium-dependent membrane and phospholipid binding proteins. Several members of the annexin family have been implicated in membrane-related events along exocytotic and endocytotic pathways. The annexin VI gene is approximately 60 kbp long and contains 26 exons. It encodes a protein of about 68 kDa that consists of eight 68-amino acid repeats separated by linking sequences of variable lengths. It is highly similar to human annexins I and II sequences, each of which contain four such repeats. Annexin VI has been implicated in mediating the endosome aggregation and vesicle fusion in secreting epithelia during exocytosis. Alternatively spliced transcript variants have been described. [provided by RefSeq, Aug 2010]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .


[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).